Frequently Asked Questions
The glucagon-like peptide 1 (GLP-1) agonists market size will be worth USD 20.15 billion by 2029.
The growth rate of the glucagon-like peptide 1 (GLP-1) agonists market is 6.10%.
Major companies in the glucagon-like peptide 1 (GLP-1) agonists market are F. Hoffmann-La Roche Ltd (Switzerland), Bristol-Myers Squibb Company (US), AstraZeneca (UK), Pfizer Inc (US), Baxter (US), Hikma Pharmaceuticals plc (UK), Amneal Pharmaceuticals, LLC (US), etc.
Rise in the cases of type 2 diabetes, obesity and related disorders & Growing adaptation of unhealthy lifestyle and genetic history of diabetes disorders are the growth drivers of the glucagon-like peptide 1 (GLP-1) agonists market.
Drugs, brand, route of administration and end users are the factors on which the glucagon-like peptide 1 (GLP-1) agonists market research is based.
